Foresite Capital is a healthcare and life sciences investment firm with a multidisciplinary team of scientists, engineers, analysts, clinicians and subject matter experts in various disciplines. We work together in a highly collaborative environment, with all investments getting attention from each member of our investment team. Roles at Foresite Capital offer exposure to multiple firms in the healthcare and life sciences industry, and the opportunity to collaborate with top-tier experts in the life sciences, data science and financial industries. We offer competitive salaries, excellent benefits, a flexible work environment, and the opportunity to learn from top thinkers in various disciplines. Foresite Capital is headquartered in San Francisco and is an equal opportunity employer. We thrive on diversity and collaboration.
Foresite Labs supports the next generation of healthcare entrepreneurs who will create innovative companies that transform the way that we discover and develop new medicines, and the way that we deliver care to patients in need. Foresite Labs systematically uses the tools of data science to create companies in healthcare that connect true changes in patient outcomes to all of the activities that are needed to develop, design and deploy therapeutics.
10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.
23andMe, Inc. is the leading consumer genetics and research company. Our mission is to help people access, understand and benefit from the human genome. The company was named by MIT Technology Review to its “50 Smartest Companies, 2017” list, and named one of Fast Company’s “25 Brands That Matter Now, 2017”. 23andMe has over 5 million customers worldwide, with ~80 percent of customers consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at www.23andMe.com.
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It’s leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.
Adaptimmune LLC is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary T-cell receptor platform that has the potential to transform the treatment of cancer. Established in 2008, the Company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (IPO) in 2015. With U.S. operations based in Philadelphia, PA, Adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast-growing team, click on the careers tab of this page.
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care’s modern era. Aetion is based in New York City, and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, and Town Hall Ventures.
Aimmune Therapeutics is a clinical-stage biopharmaceutical company founded to address the unmet medical need in food allergy, which currently has no approved treatments. Our mission is to improve the lives of people with food allergies, based on our proprietary desensitization treatments in development. Aimmune’s lead investigational drug for peanut allergy, AR101, is in Phase 3 clinical testing in North America and Europe. Headquartered in the heart of San Francisco’s biotechnology hub, Brisbane, California, Aimmune has additional offices in the Kings Cross area of London, and in Raleigh, North Carolina.
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.